We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
Read MoreHide Full Article
Key Takeaways
IDEXX's CAG recurring revenues rose 10.3% organically in Q2, supported by volumes and pricing.
IDEXX's software and imaging revenues grew about 12% organically, while recurring software rose 10%.
FX may drag Q3 revenue growth by about 70 basis points, while distributor buying can add volatility.
IDEXX Laboratories, Inc. (IDXX - Free Report) is expanding its global commercial capabilities to support continued growth in the CAG Diagnostics recurring revenue stream. The company’s software ecosystem remains a key pillar of its value proposition. However, third-party distribution and adverse foreign exchange movements pose potential challenges to IDEXX’s operations.
In the past year, this Zacks Rank #3 (Hold) stock has plunged 13.7% against the industry’s 11.5% rise and the S&P 500 composite’s 23.5% growth.
The renowned medical device company has a market capitalization of $45.59 billion. IDEXX’s earnings yield of 2.6% is well ahead of the industry’s negative 1.6% yield. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.74%.
Let’s delve deeper.
IDXX’s Tailwinds
CAG Continues to Perform Well: IDEXX continues to demonstrate strong global execution in the CAG business. Worldwide CAG Diagnostics’ recurring revenues increased 10.3% organically in the second quarter of 2026, driven by expanded volumes and approximately 4% average global net price improvement. IDEXX VetLab consumable revenues rose 14% organically, supported by net new customers, utilization gains and menu expansion. Global Reference Lab revenues increased more than 10% organically, as customer additions and broader testing utilization offset the effect of weaker U.S. wellness visits.
The inVue Dx installed base exceeded 9,000 instruments after 1,602 placements in the second quarter. Cancer Dx has surpassed 10,000 ordering clinics globally and is being expanded to include mast cell tumor detection. These trends broaden IDEXX's recurring revenue opportunity and support its 2026 organic CAG Diagnostics recurring revenue growth outlook of 9.5-10.7%.
Cloud-Based Software in Trend: IDEXX's software ecosystem continues to complement its diagnostics franchise by improving practice workflows and creating additional opportunities to integrate testing into clinical protocols. Veterinary software and diagnostic imaging revenues increased approximately 12% organically in the second quarter of 2026, while recurring software revenues grew about 10%. The cloud-native PIMS installed base continued to expand at a double-digit rate.
Image Source: Zacks Investment Research
Vello also recorded double-digit sequential growth in active users, extending IDEXX's reach into appointment generation, personalized client outreach and forward booking. The company noted that practices using ezyVet with Vello show higher wellness bloodwork inclusion rates than those using competitive on-premise PIMS, linking software adoption with diagnostic utilization. The second quarter of 2026 marked IDEXX's sixth consecutive record quarter for digital radiography system placements, supported by demand for the DR50 Plus platform.
What Ails IDXX Stock?
Foreign Exchange Exposure: IDEXX's global operations create continuing exposure to changes in foreign currency exchange rates. The company expects currency movements to create an approximately 70-basis-point drag on reported revenue growth in the third quarter. IDEXX uses hedging transactions, but its sizable international business means exchange-rate volatility can still affect reported revenues, operating profit and EPS. This exposure may periodically obscure underlying operating trends and create variability around reported financial results.
Impact of Third-Party Distribution: IDEXX continues to use third-party distributors for certain CAG instrument consumables and rapid assay products in the United States and selected international markets. These distributors purchase products from IDEXX before selling them to veterinary practices, so reported revenues can be affected by distributor inventory decisions as well as end-user demand. This can create differences between reported product sales and underlying consumption at veterinary clinics.
The risk remains relevant as IDEXX's installed base expands and recurring consumable revenues become a larger contributor to the CAG model. Distributor purchasing behavior can still add period-to-period variability and make reported trends less representative of underlying utilization.
IDXX Stock Estimate Trend
The Zacks Consensus Estimate for IDEXX’s 2026 EPS has moved north 0.9% to $14.81 over the past 30 days.
The consensus estimate for 2026 revenues is pegged at $4.72 billion, which implies a 9.7% rise from the year-ago reported number.
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% fall over the past year.
Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX’s shares have rallied 5% against the industry’s 6.2% decline over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
Key Takeaways
IDEXX Laboratories, Inc. (IDXX - Free Report) is expanding its global commercial capabilities to support continued growth in the CAG Diagnostics recurring revenue stream. The company’s software ecosystem remains a key pillar of its value proposition. However, third-party distribution and adverse foreign exchange movements pose potential challenges to IDEXX’s operations.
In the past year, this Zacks Rank #3 (Hold) stock has plunged 13.7% against the industry’s 11.5% rise and the S&P 500 composite’s 23.5% growth.
The renowned medical device company has a market capitalization of $45.59 billion. IDEXX’s earnings yield of 2.6% is well ahead of the industry’s negative 1.6% yield. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.74%.
Let’s delve deeper.
IDXX’s Tailwinds
CAG Continues to Perform Well: IDEXX continues to demonstrate strong global execution in the CAG business. Worldwide CAG Diagnostics’ recurring revenues increased 10.3% organically in the second quarter of 2026, driven by expanded volumes and approximately 4% average global net price improvement. IDEXX VetLab consumable revenues rose 14% organically, supported by net new customers, utilization gains and menu expansion. Global Reference Lab revenues increased more than 10% organically, as customer additions and broader testing utilization offset the effect of weaker U.S. wellness visits.
The inVue Dx installed base exceeded 9,000 instruments after 1,602 placements in the second quarter. Cancer Dx has surpassed 10,000 ordering clinics globally and is being expanded to include mast cell tumor detection. These trends broaden IDEXX's recurring revenue opportunity and support its 2026 organic CAG Diagnostics recurring revenue growth outlook of 9.5-10.7%.
Cloud-Based Software in Trend: IDEXX's software ecosystem continues to complement its diagnostics franchise by improving practice workflows and creating additional opportunities to integrate testing into clinical protocols. Veterinary software and diagnostic imaging revenues increased approximately 12% organically in the second quarter of 2026, while recurring software revenues grew about 10%. The cloud-native PIMS installed base continued to expand at a double-digit rate.
Image Source: Zacks Investment Research
Vello also recorded double-digit sequential growth in active users, extending IDEXX's reach into appointment generation, personalized client outreach and forward booking. The company noted that practices using ezyVet with Vello show higher wellness bloodwork inclusion rates than those using competitive on-premise PIMS, linking software adoption with diagnostic utilization. The second quarter of 2026 marked IDEXX's sixth consecutive record quarter for digital radiography system placements, supported by demand for the DR50 Plus platform.
What Ails IDXX Stock?
Foreign Exchange Exposure: IDEXX's global operations create continuing exposure to changes in foreign currency exchange rates. The company expects currency movements to create an approximately 70-basis-point drag on reported revenue growth in the third quarter. IDEXX uses hedging transactions, but its sizable international business means exchange-rate volatility can still affect reported revenues, operating profit and EPS. This exposure may periodically obscure underlying operating trends and create variability around reported financial results.
Impact of Third-Party Distribution: IDEXX continues to use third-party distributors for certain CAG instrument consumables and rapid assay products in the United States and selected international markets. These distributors purchase products from IDEXX before selling them to veterinary practices, so reported revenues can be affected by distributor inventory decisions as well as end-user demand. This can create differences between reported product sales and underlying consumption at veterinary clinics.
The risk remains relevant as IDEXX's installed base expands and recurring consumable revenues become a larger contributor to the CAG model. Distributor purchasing behavior can still add period-to-period variability and make reported trends less representative of underlying utilization.
IDXX Stock Estimate Trend
The Zacks Consensus Estimate for IDEXX’s 2026 EPS has moved north 0.9% to $14.81 over the past 30 days.
The consensus estimate for 2026 revenues is pegged at $4.72 billion, which implies a 9.7% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Teleflex (TFX - Free Report) .
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% fall over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX’s shares have rallied 5% against the industry’s 6.2% decline over the past year.